IL6R and rheumatoid arthritis: On the other hand, with the introduction of tumor necrosis factor (TNF) inhibitors, followed thereafter by application of interleukin-6 receptor (IL-6R) inhibitors, T-lymphocyte co-stimulation inhibitors (Abatacept), B cell depletion (Rituximab), as well as Janus Kinase (JAK) inhibitors, the treatment of RA in China has gradually begun to enter the targeted era [30].